Glaxo to pay out $750m over impure drugs lawsuit
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.In a rare public humiliation for a British company in the United States, GlaxoSmithKline last night formally agreed to pay $750m (£473m) to settle criminal and civil complaints stemming from a whistleblower's revelations about a shockingly degraded factory in Puerto Rico.
The case dates back to the 2003 sacking of a quality manager after she found grave shortcomings at a factory in Puerto Rico. The manager, Cheryl Eckard, warned she would retaliate by reporting what she had found to the US authorities.
What followed was an aggressive investigation by the Federal Drugs Administration that involved the seizure of medicines worth $2bn (£1.26bn), the largest such confiscation in history. The plant at Cidra was closed down last year as a consequence of the probe. Drugs affected were Avandia, Paxil – a popular anti-depressant – and Tagamet.
Ms Eckard found problems at the factory ranging from the wrong pills going in the wrong bottles, a contaminated water supply, the use of rented vans for storage and a failure to ensure the sterility of anti-cancer IV drugs.
GSK was charged with knowingly selling contaminated goods.
Ms Eckard will receive $90m (£56.8m) of the money, a reward which is likely to encourage others to reveal similar malpractice.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments